EMEA-002420-PIP01-18

Key facts

Active substance
Anti-VEGF and anti-DLL4 dual variable domain immunoglobulin (ABT-165)
Therapeutic area
Oncology
Decision number
P/0012/2019
PIP number
EMEA-002420-PIP01-18
Pharmaceutical form(s)
Powder for solution for infusion
Condition(s) / indication(s)
Treatment of malignant colorectal neoplasms
Route(s) of administration
Intravenous use
Contact for public enquiries
AbbVie Ltd

E-mail: paediatricteam@abbvie.com
Tel. +44(0)1628 561090

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating